abstract: A bioassay of @entity3 for possible carcinogenicity was conducted by administering the test material in the diet to Fischer 344 @entity2 and B6C3F1 @entity1 . Groups of 35 @entity2 of each sex were administered @entity3 at one of two doses, either 12,000 or 24,000 ppm, 5 days a week for 78 weeks, then observed for an additional 28 weeks. Matched-control groups consisted of 15 untreated @entity2 of each sex. All surviving @entity2 were killed at 106 or 107 weeks. Groups of 35 @entity1 of each sex were administered @entity3 at one of two doses, either 25,000 or 50,000 ppm, 5 days a week for 78 weeks, then observed for an additional 24-26 weeks. Matched-control groups consisted of 15 untreated @entity1 of each sex. All surviving @entity1 were killed at 102-104 weeks. Mean body weights of the treated @entity2 and @entity1 were lower than those of the corresponding matched controls during the entire study; however, survival was not significantly affected by treatment in either species. In both sexes of both species, survival was considered to be adequate for meaningful statistical analyses of the incidence of @entity0 . In both the @entity2 and the @entity1 , a variety of @entity0 were found in both @entity3 -treated and control groups. None of the @entity0 were present at a statistically significant increased incidence in treated groups of either species as compared with control groups and were not considered to be compound related. It is concluded that under the conditions of this bioassay, @entity3 was not carcinogenic for either Fischer 344 @entity2 or B6C3F1 @entity1 .

title: Bioassay of XXXX for possible carcinogenicity.

answer: @entity3


abstract: UNASSIGNED: Dietary patterns with @entity1 have been recommended, but the relative contributions of individual foods and food components, alone or in combination, remain undefined. Male @entity10 (-/-) @entity0 were fed either a purified AIN-93G control diet, a @entity11 ( @entity11 ), or a @entity11 with 10% @entity3 powder (TP), 2% soy germ (SG), or the combination, for 4 wk (n = 10 per group). Plasma total @entity2 and @entity6 were measured with enzymatic colorimetric kits, and @entity14 ( @entity14 ) was measured by ELISA. Liver lipids were extracted with @entity9 : @entity5 , and @entity6 , free and esterified @entity2 measured with enzymatic colorimetric kits. Expression of @entity16 , @entity15 , @entity12 , and @entity13 in the liver was determined by quantitative polymerase chain reaction. Sections of the aortic root and aorta were cut and stained with @entity7 and @entity8 (H_E) to assess extent of @entity4 . @entity11 -fed animals had greater liver and adipose weights, plasma @entity2 and @entity14 , hepatic lipids, and @entity4 than AIN-93G animals. TP and SG did not decrease @entity4 as measured by H_E-stained sections of the aortic root, aortic arch, and descending aorta. The TP diets further increased plasma @entity2 , but also led to increased expression of the @entity12 /8 transporters involved in @entity2 efflux. Addition of SG alone to the @entity11 attenuated @entity11 -induced increases in plasma @entity2 , liver lipids, and gonadal adipose weight. The results of this study do not support the use of either TP or SG for reduction of @entity4 , but suggest some beneficial effects of SG on lipid metabolism in this model of @entity1 .

title: Effects of @entity3 and Soy Germ on Lipid Bioaccumulation and @entity4 in @entity10 (-/-) XXXX .

answer: @entity0


abstract: Noroviruses are the leading cause of acute @entity4 outbreaks worldwide. The majority of norovirus outbreaks are caused by genogroup II.4 (GII.4). Novel GII.4 strains emerge every 2 to 4 years and replace older variants as the dominant norovirus. Novel variants emerge through a combination of recombination, genetic drift, and selection driven by population immunity, but the exact mechanism of how or where is not known. We detected two previously unknown novel GII.4 variants, termed GII.4 UNK1 and GII.4 UNK2, and a diverse norovirus population in fecal specimens from immunocompromised individuals with @entity1 after they had undergone bone marrow transplantation. We hypothesized that immunocompromised individuals can serve as reservoirs for novel norovirus variants. To test our hypothesis, metagenomic analysis of viral RNA populations was combined with a full-genome bioinformatic analysis of publicly available GII.4 norovirus sequences from 1974 to 2014 to identify converging sites. Variable sites were proportionally more likely to be within two @entity2 (P < 0.05) of positively selected sites. Further analysis using a hypergeometric distribution indicated that polymorphic site distribution was random and its proximity to positively selected sites was dependent on the size of the norovirus genome and the number of positively selected sites.In conclusion, random mutations may have a positive impact on driving norovirus evolution, and immunocompromised individuals could serve as potential reservoirs for novel GII.4 strains. IMPORTANCE: Norovirus is the most common cause of @entity3 in the United States. Every 2 to 3 years novel norovirus variants emerge and replace dominant strains. The continual emergence of novel noroviruses is believed to be caused by a combination of genetic drift, population immunity, and recombination, but exactly how this emergence occurs remains unknown. In this study, we identified two novel GII.4 variants in immunocompromised bone marrow transplant @entity0 . Using metagenomic and bioinformatic analysis, we showed that most genetic polymorphisms in the novel variants occur near 0 to 2 @entity2 of positively selected sites, but the distribution of mutations was random; clustering of polymorphisms with positively selected sites was a result of genome size and number of mutations and positively selected sites. This study shows that immunocompromised @entity0 can harbor infectious novel norovirus variants, and although mutations in viruses are random, they can have a positive effect on viral evolution.

title: RNA populations in immunocompromised XXXX as reservoirs for novel norovirus variants.

answer: @entity0


abstract: STUDY DESIGN: Retrospective study of consecutive @entity0 series. OBJECTIVES: To review the radiographic and clinical results of @entity0 with preoperative fixed sagittal imbalance treated with combined anterior and posterior arthrodesis, and to determine factors that predict clinical outcome. SUMMARY OF BACKGROUND DATA: Combined anterior and posterior arthrodesis of the spine is useful in the management of fixed @entity1 involving the coronal and sagittal planes. The specific indications for combined surgery in the @entity0 with regional and global imbalance have not been well defined. METHODS: Retrospective review of 25 consecutive @entity0 treated with combined anterior and posterior spinal arthrodesis. Inclusion criteria included a preoperative global sagittal imbalance of at least 5 cm. Outcome variables included radiographic measures of preoperative, postoperative, and follow-up films, and a clinical assessment using the Modified SRS Outcomes Instrument and a review of @entity3 . RESULTS: Twenty-five consecutive cases were reviewed. Mean age was 58 years (range 38-77), and mean follow-up was 55 months (range 24-81) for clinical and 44.5 (range 24-81) months for radiographic outcome variables. The mean preoperative sagittal imbalance was 10.5 cm (range 5.2-23.3), which improved to 2.9 cm (range 0-12.6) after surgery, and was maintained as 3.3 cm (range 0-13.5) at follow-up. @entity4 was -23 degrees (range +40 to -47) before surgery, and increased to -42 degrees at follow-up (range -20 degrees to -60 degrees ), an increase of 19 degrees. @entity0 with preoperative regional hypolordosis in the lumbar spine that was corrected surgically had the highest postoperative scores. The mean score for @entity0 satisfaction with surgical management was 4.45 (range 2.5-5). Correlation analysis of clinical outcome domains demonstrated that @entity0 satisfaction correlated poorly with domains of @entity2 (r = 0.37, P = 0.1) and function (r = 0.4, P = 0.09). Within the domains, self-image showed highest correlation with @entity0 satisfaction (r = 0.65, P = 0.006) and total score (r = 0.89, P = 0.0001). CONCLUSIONS: @entity0 with global sagittal imbalance of the spine were effectively treated with a combined anterior and posterior arthrodesis as measured by radiographic parameters. @entity0 satisfaction with surgery, and overall clinical outcomes were best in cases that resulted in an @entity4 . The subset of @entity0 with preoperative regional hypolordosis of the lumbar spine has better outcomes than those with @entity4 in the physiologic range.

title: Management of fixed XXXX : outcome of combined anterior and posterior surgery.

answer: @entity1


abstract: BACKGROUND: The benefits of antithrombotic therapy in chronic @entity4 ( @entity4 ) have been established in clinical trials, but there is a paucity of data on outcomes in practice. AIMS: The objective was to establish a large ongoing database of @entity0 with @entity4 , to enable the accurate determination of clinical outcomes. METHODS: A retrospective review of the medical records for consecutive @entity0 who had @entity4 documented on electrocardiogram at the major teaching hospital in Tasmania between 1 January 1997 and 30 June 1999 was performed. An extensive range of demographic and clinical variables was recorded for all @entity0 with chronic or paroxysmal @entity4 . RESULTS: The 505 @entity0 (60% males) included in the database had a median age of 76 years. According to risk stratification criteria, 79% of the @entity0 with previously diagnosed chronic or paroxysmal @entity4 had a high risk of developing @entity1 at the time of admission to hospital care. However, only one-third (34%) of these @entity0 were receiving @entity5 (or @entity5 plus @entity2 ), with almost one-quarter (24%) receiving no antithrombotic agent. The annual incidence of @entity1 was 3.4% (1.5-6.4%; 95% CI) when taking @entity5 , compared to 7.0% (5.2-9.4%) for @entity0 not taking @entity5 and 7.8% (5.4-11.1%) for @entity0 taking @entity2 . The annual incidence of @entity3 complications in @entity0 taking @entity5 was 14.2% (10.0-19.5%) overall and 3.4% (1.5-6.4%) for major @entity3 . In @entity0 not taking @entity5 , the overall annual incidence of @entity3 was 8.4% (6.3-10.9%) and 3.9% (2.5-5.7%) for major @entity3 . CONCLUSIONS: @entity5 is underused in @entity0 with @entity4 . In clinical practice, @entity5 confers a similar @entity1 risk reduction to that observed in trials, with an increase in incidence of only minor @entity3 complications. @entity2 did not appear to reduce the risk of @entity1 .

title: Outcomes in the management of XXXX : clinical trial results can apply in practice.

answer: @entity4


abstract: UNASSIGNED: While selective @entity5 inhibitors have demonstrated improved outcomes in @entity0 with metastatic @entity5 @entity7 mutant @entity4 , management of brain @entity1 prior to and during therapy presents challenges. Stereotactic radiosurgery (SRS) is an effective treatment for @entity4 brain @entity1 , but there is limited safety and efficacy data on the use of SRS during @entity5 therapy. An analysis was performed of @entity0 with @entity4 and brain @entity1 treated with SRS while on @entity6 . MRI scans were reviewed post-SRS to evaluate local control (LC) as well as distant control. We identified 80 metastatic @entity2 treated in 24 @entity0 . The median planning target volume was 0.28  cm(3) (range 0.05-4.19  cm(3)), and lesions were treated to a median dose of 24  Gy (range 15-24  Gy). The median follow up was 5.1  months (range 2-25.2  months). Eight (10  %) lesions showed progression at a median of 6.1  months (range 2-20.1  months) following SRS. Kaplan-Meier LC estimates at 6 and 12  months were 92 and 75  %, respectively. Fourteen (58  %) @entity0 were noted to have distant brain failure at a median of 3.4  months (range 1.9-16.1  months) following treatment with SRS. Median overall (OS) from the date of SRS was 7.2  months (range 1.5-26.8  months) with a median of 11.9  months (range 1.5-28.5  months) since the date of brain @entity1 diagnosis. There was no evidence of increased @entity3 with the combination of SRS and @entity6 . SRS to brain @entity1 appears to be both safe and effective for @entity0 treated concurrently with @entity5 inhibitors.

title: LINAC-based stereotactic radiosurgery to the brain with concurrent XXXX for @entity4 @entity1 .

answer: @entity6


abstract: BACKGROUND/AIM: Mucosa-associated lymphoid tissue (MALT) @entity3 accounts for 5-17% @entity5 ( @entity5 ). The molecular pathogenesis of @entity4 is not well-established. The aim of this study was to evaluate immunohistochemically determined nuclear coexpression of @entity7 and @entity6 ( @entity6 ) in @entity1 cells of @entity8 and its impact on the patogenesis and outcome of the disease. METHODS: Medical records of 35 @entity0 with newly diagnosed @entity8 were analyzed and biopsy specimens were immunostained for @entity7 and @entity6 expression ( @entity9 subunit). RESULTS: The median age of 35 @entity0 diagnosed with @entity8 was 63.5 years (male/female = 21/14). Symptoms were present in 23/35 (65.7%) @entity0 with the weight loss as the most common symptom. Gastric @entity4 were usually localized in the stomach corpus and corpus and antrum (45.7% and 31.2%, respectively). H. @entity2 was confirmed in 20 out of 30 (66.7%) @entity0 . Treatment options were as follows: immunochemotherapy in 10 (28.5%) @entity0 , surgery in 9 (25.8%) @entity0 , combined surgery and chemotherapy in 14 (40%) @entity0 and supportive measures in 2 (5.7%) @entity0 . Complete remission was achieved in 13 (37.10/) @entity0 and partial remission in two (5.7%/) @entity0 . Sixteen (45.7%/) @entity0 had disease progression (p < 0.001). Cytoplasmatic expression of @entity7 in @entity1 cells was detected in 19 (54.3%) specimens. Nuclear expression was detected in no specimen. Cytoplasmic expression of @entity6 was present in 22 (65.7%) specimens, but nuclear expression was not detected in any specimens. CONCLUSION: Nuclear expressions (activation)of @entity9 subunit and @entity7 were not detected in specimens of @entity8 . The correlation of nuclear coexpression of @entity7 and @entity6 in @entity8 was not established. These results indicate that other mechanisms and signal pathways are active in lymphogenesis of @entity8 , as that apoptotic inhibition is not the main, nor the only mechanism in tumorogenesis.

title: XXXX aberations and @entity6 activation involving @entity9 are absent or rare in primary @entity8 .

answer: @entity7


abstract: The National Institute on Aging and Reagan Institute (NIA-RI) criteria, and other neuropathologic criteria for @entity1 ( @entity1 ), were compared with the clinical diagnosis of @entity2 in a well defined population of Catholic sisters. The 47- @entity0 subset examined in this study were college educated and lacked complicating conditions such as @entity5 or @entity4 . Sixteen @entity0 had a clinical diagnosis of @entity2 . The NIA-RI criteria imply a perfect correlation between @entity3 ( @entity3 ) density and neurofibrillary tangle distribution. However, @entity3 density often did not coincide with tangle distribution. As a result, it was not possible to categorize many of the @entity0 using the NIA-RI guidelines. The 'high likelihood' category of the NIA-RI criteria for @entity1 research settings (neocortical Braak stage and frequent neocortical @entity3 ) had relatively high specificity (90% of nondemented @entity0 did not meet this criteria). However, only half of the demented @entity0 were in this category. Neuropathologic criteria requiring the presence of neocortical tangles (rather than neocortical Braak stage) had relatively high sensitivity, accounting for 87-94% of @entity0 with @entity2 , but also included 32-35% of nondemented @entity0 . Criteria based on neocortical @entity3 or senile plaques had 100% sensitivity, but a majority of nondemented @entity0 also met these criteria. The results support consideration of both tangles and @entity3 for the neuropathologic diagnosis of @entity1 , but indicate that refinement of the NIA-RI criteria is necessary. A possible refinement is suggested for further consideration.

title: Comparison of neuropathologic criteria for the diagnosis of XXXX .

answer: @entity1


abstract: BACKGROUND: Excessive bodyweight contributes to a myriad of risk factors for @entity1 , and multiple reports have demonstrated that parents influence the development of their @entity0 's behaviors that contribute to bodyweight. However, studies that include considerations for cultural influences are limited, and methodology that considers direct reports from young adults and their parents across cultures does not exist. METHODS: A sample of young adults (N   =   327) and their parents in the U.S. and in China were recruited and completed a series of questionnaires in two cycles (2010 and 2014). With correlation and multiple regression analyses, parents' characteristics, behaviors, and parental authority styles were examined and compared to weight-related @entity2 and bodyweight of their young-adult @entity0 . Additionally, similarities and differences of parental influences between the two cultures were explored. RESULTS: Parents' body mass indexes (BMIs) and dietary behaviors were positively associated with those of their young adult @entity0 in the mixed-culture sample (P   <   .001 for both). When controlling for gender, at high levels of authoritarian and permissive parental authority, the relationships between young adults' and their parents' BMIs were negative for U.S. @entity0 and positive for Chinese @entity0 (P   <   .05 for both). Further, at high levels of authoritarian parenting, the relationship between young adults' and their parents' dietary consumption behaviors was negative for U.S. @entity0 and positive for Chinese @entity0 (P   <   .001). CONCLUSIONS: This study provides evidence that the development of life-long @entity2 that contribute to BMI are significantly influenced by parents' behaviors and parenting styles. Moreover, an interaction of parental characteristics and cultural norms is indicated.

title: Parental influences on weight-related XXXX in western and eastern cultures.

answer: @entity2


abstract: INTRODUCTION: African Americans have a greater incidence of @entity1 than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed- @entity5 -bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. @entity3 - @entity5 -bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the @entity0 were African American. PointBreak had negative findings; PemCBev did not demonstrate superior @entity4 ( @entity4 ). MATERIALS AND METHODS: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and @entity6 versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. RESULTS: Of 939 intent-to-treat (ITT) @entity0 , 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, @entity4 (HR, 1.125; P  = .525), progression-free survival (PFS) (HR, 1.229; P  = .251), response (P  = .607), and @entity2 profiles were similar in African Americans versus whites. For African Americans, @entity4 (HR, 1.375; P  = .209), PFS (HR, 0.902; P  = .670), response (P  = 1.000), and @entity2 profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in @entity4 (HR, 0.661; P  = .191) or PFS (HR, 0.969; P  = .915) in @entity6 versus community practice settings. CONCLUSION: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or @entity2 profiles. Consistent with the ITT population negative trial result, for African Americans, the median @entity4 was not superior for either arm. For African Americans, PFS and @entity4 were similar in the  @entity6 and community settings. Additional outcomes data for African Americans should be collected in @entity1 studies.

title: Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed- @entity5 -Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus XXXX - @entity5 -Bevacizumab Followed by  Maintenance Bevacizumab in @entity0 With Stage IIIB/IV Nonsquamous Non-Small-Cell @entity1 .

answer: @entity3


abstract: OBJECTIVE: This study aims to discover the individual, microsocial and macrosocial factors and the milieu which lead to today's pattern of adolescent @entity1 consumption. DESIGN: A descriptive, crossover study without randomisation. SETTING: Primary Care. School population from the Bajo-As  n Centre 1 Health Area, Cantabria. @entity0 AND OTHER @entity0 : Adolescents between 11 and 15 in school. A group of key @entity0 from the population was also included. MEASUREMENTS AND MAIN RESULTS: The PRECEDE health education model was applied to three groups of adolescents. A discussion group with key @entity0 connected with adolescents and @entity1 was formed. The main results were the wrong information recognised by those involved, the easy access of minors to @entity1 , the influence of social acceptance, scant social skills and the lack of alternatives. CONCLUSIONS: In view of these results it is clear that action must be taken. Therefore, a community-based prevention programme for adolescents was set up, its key points being information to parents and pupils, ways of communicating and social skills, creation of alternatives and the creation of a local committee to monitor the rules on provision of @entity1 to minors.

title: [Evaluation of risk factors of XXXX consumption by adolescents].

answer: @entity1


abstract: OBJECTIVES: Describe the methodologies and study population of the @entity1 Outcomes in Veterans Study (DOVES). RESEARCH DESIGN AND METHODS: Prospective, multicenter, observational study of Southwestern veterans with stable, @entity6 -treated @entity3 2 @entity1 . Subjects were randomly selected from pharmacy records and were required to be using at least one long-acting @entity6 preparation daily. Baseline psychosocial evaluations included @entity2 , social and cultural barriers to care, self-care behaviors, and @entity5 risk factors. Clinical measurements included self-reported @entity5 , hemoglobin A1c (HbA1c), blood pressure, blood lipids, and body mass index (BMI). A subset of subjects completed a protocol of four times daily self-monitored blood @entity4 testing for 8 weeks. Subjects were followed for 12 months. Principal endpoints included glycemic control, the occurrence of @entity7 , and control of @entity5 risk factors. RESULTS: We enrolled 338 subjects. The mean (+/-S.D.) age was 65.1+/-9.7 years and 3.8% were @entity0 . At baseline, over two-thirds of subjects reported @entity5 . Nearly three-quarters had limited physical activity. Among subjects younger than 65 years, 53% considered themselves disabled for work. Despite the high prevalence of @entity5 , 43.8% had an HbA1c >/=8.0%. Many subjects were sedentary, 62.1% had a BMI of 30 kg/m(2) or above, and 22.2% were still smoking. CONCLUSIONS: Detailed measurements of @entity2 , self-care behaviors, and risk factor control are feasible in this elderly, debilitated population. Although the prevalence of complications and self-rated disability was high, @entity5 risk factors were poorly controlled in a substantial proportion of subjects.

title: Risk factor management in stable, @entity6 -treated @entity0 with XXXX 2 @entity1 : the @entity1 Outcomes in Veterans Study.

answer: @entity3


abstract: BACKGROUND: Abnormal microcirculation has been suggested in hearts with pathological conditions, particularly in @entity4 hearts, even in the presence of normal epicardial coronary arteries. However, the morphology of coronary capillaries has not been well investigated in those hearts. METHODS: Ultrastructural morphometry of the capillaries in 47 endomyocardial biopsy specimens taken from 30 @entity0 was performed. @entity0 : Six @entity0 had @entity3 with @entity1 -like features ( @entity5 -like HCM), six had HCM, six had @entity5 , five had postmyocarditis, and seven were normal subjects. RESULTS: The short axial diameters of capillaries were similar among the groups. Abnormal stenosis of more than 90% luminal narrowing was found in 31% of capillaries of the @entity5 -like HCM group, 16% of the HCM group, 13% of the @entity5 group, 11% of the postmyocarditis group, and 2% of the normal subjects. Mean (SD) stenosis of the lumen was most severe in @entity5 -like HCM (78(8)%), and more severe in HCM (67(9)%), @entity5 (66(8)%), and postmyocarditis (68(4)%) than normal subjects (56(8)%). The mean cross sectional areas of capillaries were similar among the groups; however, the endothelial cellular area was significantly (p < 0.05) greater in @entity5 -like HCM (24.2 (8.2) microns2) than in normal subjects (14.7 (1.8) microns2), indicating that capillary narrowing was due to the increased volume of capillary endothelial cells. The endothelial cells of the stenosed capillaries showed severely oedematous changes of the cytoplasm wholely or partially, but the cytoplasmic organelles and nuclei appeared intact. CONCLUSION: Narrowing of the coronary capillaries may be of pathophysiological significance in @entity2 in @entity4 hearts, particularly in @entity0 with @entity5 -like HCM.

title: Luminal narrowing of coronary capillaries in XXXX @entity4 hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens.

answer: @entity0


abstract: The objective of this study was to determine if the addition of @entity8 (MA), a modulator of @entity5 -mediated drug resistance, to first-line cytotoxic therapy in @entity0 with limited and advanced stage @entity1 ( @entity1 ) would improve median time to disease progression and median overall survival. Secondary outcomes evaluated were response rates and @entity0 symptom profile. Between 1992 and 1995, 130 eligible @entity0 were randomized in a double-blind fashion to receive standard first-line therapy consisting of alternating courses of @entity3 / @entity2 / @entity6 and @entity7 / @entity4 (and thoracic radiotherapy for limited stage @entity0 ), along with either placebo or MA 160 mg t.i.d. for 8 days commencing 3 days before initiation of each cycle of chemotherapy. Treatment was continued for a maximum of six cycles. A total of 130 eligible @entity0 were randomized, 65 to each arm. Fifty-two per cent of @entity0 had limited disease and 48% had advanced disease. The median time to disease progression in limited stage disease was 46 weeks in the placebo arm and 43 weeks in the MA arm (P = 0.71) and in advanced stage disease was 28 weeks in the placebo arm and 27 weeks in the MA arm (P = 0.92). The median overall survival in limited stage disease was 75 weeks in the placebo arm and 75 weeks in the MA arm (P = 0.56) and in advanced stage disease was 41 weeks in the placebo arm and 39 weeks in the MA arm (P = 0.96). There was no consistent statistical difference in response rates or @entity0 symptom profiles between the two treatment arms. The addition of MA, in the dose and schedule used, to standard first-line cytotoxic therapy in @entity1 did not result in a significant improvement in response rates, symptom profile, median time to disease progression or overall survival.

title: Results of a phase III, double-blind, placebo-controlled trial of @entity8 modulation of @entity5 -mediated drug resistance in the first-line management of XXXX .

answer: @entity1


abstract: @entity5 ( @entity5 ) is subdivided into syndromes based on clinical and EEG features. PURPOSE: The aim of this study was to characterise all cases of @entity5 with supportive EEG abnormalities in terms of gender differences, @entity2 types reported, @entity5 syndromes, family history of @entity1 and EEG findings. We also calculated the limited duration prevalence of @entity5 in our cohort. METHODS: Data on abnormal EEGs were collected retrospectively from two EEG databases at two tertiary referral centres for neurology. Clinical information was obtained from EEG request forms, standardised EEG questionnaires and medical notes of @entity0 . RESULTS: two hundred twenty-three @entity0 met our inclusion criteria, 89 (39.9%) male and 134 (60.1%) females. @entity2 were the most common @entity2 type reported, 162 (72.65%) having a generalised tonic @entity2 (GTCS) at some time. @entity5 with GTCS only (EGTCSA) was the most common syndrome in our cohort being present in 94 @entity0 (34 male, 60 female), with 42 (15 male, 27 female) @entity0 diagnosed with @entity4 ( @entity4 ), 23 (9 male, 14 female) with @entity3 ( @entity3 ) and 20 (9 male, 11 female) with @entity3 ( @entity3 ). EEG studies in all @entity0 showed generalised @entity1 . CONCLUSIONS: More @entity0 than @entity0 were diagnosed with @entity1 . @entity2 were the most common @entity2 type reported. EGTCSA was the most frequent syndrome seen. Gender differences were evident for @entity3 and @entity4 as previously reported and for EGTCSA, which was not reported to date, and reached statistical significance for EGTCA and @entity4 .

title: A study of XXXX in an Irish population.

answer: @entity5


abstract: OBJECTIVE: To assess the level of serum lipoprotein(a) [ @entity6 ] in nonobese and @entity2 @entity5 subjects with android body distribution. RESEARCH DESIGN AND METHODS: Serum @entity6 levels were measured in 30 long-standing @entity5 @entity0 (duration of @entity1 12.5 +/- 3 years, mean +/- SD), with 15 of the @entity0 being @entity2 of android distribution (BMI > 30 kg/m2 and waist-to-hip ratio > 0.8). In addition, there were 15 android @entity2 nondiabetic subjects and 10 healthy subjects serving as the control group. RESULTS: All groups of @entity0 in this study ( @entity1 , and @entity2 @entity1 ) showed significantly higher levels of @entity6 than the healthy control group. @entity6 concentrations were significantly higher in @entity5 @entity0 with android type of @entity2 than in nondiabetic androids (24.1 +/- 5.6 vs. 14.8 +/- 2.4 mg/dl, P < 0.001). Significantly greater levels of @entity6 were found in nonobese subjects with @entity1 when compared with @entity2 subjects without @entity1 (22.3 +/- 4.1 vs. 14.8 +/- 2.4 mg/dl, P < 0.001). Furthermore, @entity6 serum concentrations were not dependent on the degree of glycemic control (controlled @entity5 23.6 +/- 5.0 vs. uncontrolled @entity5 21.4 +/- 2.7 mg/dl, NS), but were much greater in subjects with @entity1 complicated by @entity3 (complicated 26.3 +/- 5.0 vs. uncomplicated 20.5 +/- 2.7 mg/dl, P < 0.001). No correlation was found between @entity6 and other lipid parameters in this study. CONCLUSIONS: @entity6 levels are significantly elevated in both @entity2 and nonobese @entity5 @entity0 regardless of the degree of glycemic control. @entity6 is an independent risk factor showing greater elevations in those subjects complicated with @entity4 .

title: Lipoprotein(a) in @entity2 and XXXX .

answer: @entity5


abstract: PURPOSE: We have shown previously that Bruch's membrane (BM) aging decreases @entity2 ( @entity2 ) phagocytosis. Herein, we determine the effects of BM reengineering on @entity2 phagocytosis. METHODS: BM explants were dissected from young and old donor eyes. Some old BM explants were reengineered by cleaning with @entity4 and/or coating with extracellular matrix (ECM) ligands. @entity0 cell-derived ECM (ARPE-ECM) modified ("aged") by @entity5 was subjected to similar treatments. @entity0 cells were then cultured to confluence onto the different surfaces. Fluorescently-labeled @entity1 rod outer segments (ROS) were fed to cells with or without aVb5 integrin antibody. Image acquisition and phagocytosis quantification was performed by fluorescence microscopy and ImageJ analysis. RESULTS: Cleaning old donor-derived BM with detergent does not increase the uptake of ROS, but a combination of cleaning and coating with ECM ligands significantly increases @entity2 phagocytosis (54.9    6.2 vs. 83.5    6.5 arbitrary units; P < 0.05) to levels closer to young donor BM (123.6    9.9 arbitrary units). Similar effects were observed on @entity3 -modified ARPE-ECM subjected to the same treatments. Incubation of aVb5 blocking antibody with ROS significantly decreased @entity2 phagocytosis. CONCLUSIONS: The detrimental effects of aging BM on @entity2 phagocytosis can be reversed by reengineering the BM surface with detergent cleaning and recoating with ECM ligands. TRANSLATION RELEVANCE: These results demonstrate that the therapeutic success of transplanted @entity2 cells may require, at least in part, reengineering of diseased BM to make it a more suitable environment for attachment, survival and proper functioning of the @entity2 .

title: Reengineering @entity0 Bruch's Membrane Increases Rod Outer Segment Phagocytosis by XXXX Retinal Pigment Epithelium.

answer: @entity0


abstract: PURPOSE: To describe the frequency, nature, trends, predictors, and outcomes of chemotherapy-related hospitalizations (CRHs) among a nonselected population of @entity1 @entity0 treated at a community @entity1 center, and to explore the feasibility of implementing continuous quality improvement methodologies in routine oncology practice. METHODS: We conducted a prospective cohort study of consecutive adult @entity1 @entity0 who received chemotherapy at a community @entity1 center January 2003 to December 2006. Demographic, comorbidity, diagnosis, treatment, and laboratory data were collected via medical record abstraction. Hospitalizations were classified as chemotherapy related or unrelated by a multidisciplinary panel. @entity0 who experienced CRHs were compared with those who did not. Using a randomly sampled subset of cases and controls, we built a logistic regression model to identify independent predictors of @entity4 . RESULTS: Of 2,068 chemotherapy recipients, 179 (8.7%) experienced 262 CRHs. Most hospitalizations were not chemotherapy related (73.7%). The mean monthly rate of @entity4 was 1.5%, the median length of stay was 5 days, the most common type of @entity4 was gastrointestinal (46.1%) followed by infectious (31.4%), and 0.9% of chemotherapy recipients had a fatal @entity4 . Significant predictors of @entity4 included having a comorbidity score of 3-4 versus 0 and having a higher @entity3 level. CONCLUSIONS: Although the vast majority of chemotherapy recipients did not experience a @entity4 , these events were, unfortunately, not without serious consequences. Care should be taken when offering chemotherapy to @entity0 with multiple comorbid conditions. Systematic efforts to monitor @entity2 can lead directly to improvements in quality of care.

title: Chemotherapy-related hospitalization among community XXXX center @entity0 .

answer: @entity1


abstract: BACKGROUND/PURPOSE: Percutaneous internal ring suturing (PIRS) is a minimally invasive method for repair of pediatric @entity1 . In this study we report our experience with PIRS. METHODS: All @entity0 >10kg presenting to our institute between June 2013 and March 2015 with a diagnosis of indirect @entity1 or communicating hydrocele underwent laparoscopic repair using PIRS technique. @entity0 ' gender, age at surgery, side of @entity1 /communicating hydrocele at diagnosis, peroperative findings, surgical and anesthesia times plus follow-up findings were collected. RESULTS: Two-hundred thirteen @entity0 underwent 250 procedures. @entity1 or communicating hydrocele was diagnosed on the right side in 113 (53.1%), the left side in 75 (35.2%) and bilaterally in 25 @entity0 (11.7%). @entity2 was found in 35 @entity0 (16.4%). Mean surgery time was 14.3min for unilateral and 20.4min for bilateral PIRS, and mean anesthesia time was 33.6min for unilateral and 39.1min for bilateral PIRS. Average follow-up time was 9.6months. Recurrence was seen in 3 (1.4%) and complications in 6 @entity0 (2.8%). CONCLUSION: PIRS is a simple, safe and effective method for the treatment of @entity1 and communicating hydrocele in @entity0 .

title: Percutaneous internal ring suturing is a safe and effective method for the minimal invasive treatment of pediatric XXXX : Experience with 250 cases.

answer: @entity1


abstract: PURPOSE: Adherence to treatment protocols to manage @entity2 , @entity5 , and @entity4 is associated with reduced levels of mortality and morbidity in @entity1 @entity0 . However, the extent of research translation in this area is unclear. The aim of this study was to determine whether there is an evidence-practice gap in the management of @entity2 , @entity5 , and @entity4 in an @entity1 . DESIGN: Medical records were audited to determine whether clinical practice was consistent with best practice, as defined by treatment protocols used within the Quality in @entity1 Care study. METHODS: Data were collected regarding the assessment and management of @entity2 , @entity5 , and @entity4 . Reasons for variance from "best practice" care were noted. The case note audit took place in an @entity1 in a large teaching hospital in Australia. @entity0 were 53 @entity1 survivors discharged from the study site over a 6-month period in 2013. FINDINGS: Care processes did not consistently reflect best practice. Temperature was monitored 4-6 hourly in 62% of the @entity0 . Fifty-three percent of the @entity0 had a fingerprick blood @entity3 level on admission to the @entity1 unit and only 4% of the @entity0 were monitored 6th hourly. Data showed that 83% of the @entity0 received a swallow assessment within 24  hours by a speech pathologist. Thirty percent of the @entity0 were given food and fluids before speech assessment. Only eight @entity0 (26%) directly admitted to the @entity1 unit received best practice assessment of temperature, blood @entity3 , and @entity4 . CONCLUSIONS: Current practice does not reflect best practice. Barriers to research translation are currently unclear but must be overcome to improve care quality for @entity1 survivors. Multifaceted interventions to ensure uptake of care protocols are required. CLINICAL RELEVANCE: Consistent provision of evidence-based practice needs to be available to ensure @entity0 are provided with the best nursing care following @entity1 .

title: Management of Fever, @entity5 , and XXXX in an @entity1 Unit.

answer: @entity4


abstract: The aim of this article is to describe potential alternatives to @entity0 no longer eligible for management with @entity4 for @entity2 according to the recommendations by the European Medicines Agency. A systematic search of Pubmed was done for papers on @entity3 efficacy of various treatments for @entity2 , and potential harms especially in terms of cardiovascular events and @entity1 . The results showed that drugs more efficacious in terms of relative risk reduction of @entity3 than @entity4 were @entity9 , @entity10 , @entity14 , and denosumab. @entity6 , as for @entity17 , may be associated with an increased risk of @entity13 and fatal @entity1 . In terms of cardiovascular events special attention may be given to @entity7 supplements. Thus, @entity0 at risk of @entity1 and ischemic @entity5 such as @entity11 should not use @entity4 . Ideally more efficacious drugs in terms of @entity3 reduction should be used such as @entity9 , @entity10 , @entity14 or denosumab. @entity6 may pose a special problem as this too may be associated with an increased risk of @entity1 . Other less-potent drugs in terms of @entity3 reduction should only be used if no alternatives are available ( @entity16 , @entity15 , @entity18 ). @entity8 or analogs may be used for a limited time interval in specially selected @entity0 and needs to be followed up with antiresorptive treatment to prevent @entity12 . However, it should be remembered that no head-to-head comparison studies exist.

title: New strategies for @entity2 XXXX previously managed with @entity4 .

answer: @entity0


abstract: BACKGROUND: Safety profiles of biologics for treatment of @entity3 are limited to data from randomized controlled trials. There is a need for comparative safety reports of biologics based on data from clinical practice. OBJECTIVE: We sought to estimate and compare the incidence of adverse events (AEs) leading to withdrawal of biologics (etanercept, infliximab, adalimumab, and ustekinumab) in the treatment of @entity3 . METHODS: We conducted a multicenter retrospective chart review from September 2005 to September 2014. Incidence proportion and rate of AEs leading to withdrawal by biologic agent and AE were calculated. RESULTS: For 545 treatments administered in 398 @entity0 , 22 (4.04%) AEs were associated with withdrawal, for a rate of 1.97/100 @entity0 -years (95% confidence interval [CI] 1.32-2.94). Common AEs were injection-/infusion-site reactions (0.55%, 0.92%, 0%, and 0% for etanercept, infliximab, adalimumab, and ustekinumab, respectively); @entity2 (0%, 0.18%, 0.55%, 0.18%); and @entity1 (0.18%, 0.18%, 0%, 0.37%). LIMITATIONS: Possible incompleteness of chart details and small study population limit the conclusiveness of findings. CONCLUSION: Biologic agents for treatment of @entity3 are safe; AEs associated with withdrawal occurred in 4% of all administered biologic therapies. It does not appear that real-world @entity0 encounter more AEs with biologics than @entity0 in clinical trials.

title: Adverse events resulting in withdrawal of biologic therapy for XXXX in real-world clinical practice: A Canadian multicenter retrospective study.

answer: @entity3


abstract: GOALS: To test the hypothesis that the use of a low-residue breakfast (LRB) the day prior to colonoscopy was not inferior to consuming @entity3 ( @entity3 ) in @entity0 undergoing outpatient colonoscopy with a @entity1 ( @entity2 ) bowel preparation. BACKGROUND: Optimal colon cleansing is essential for complete visualisation of the mucosa during colonoscopy. Few studies have examined the effect of diet on the quality of bowel cleansing or tolerance in @entity0 using a @entity2 bowel preparation for colonoscopy. METHODS: Randomised, single-blinded non-inferiority trial. Adult @entity0 scheduled for outpatient colonoscopy with @entity2 solution were randomised to an LRB followed by clear fluids or @entity3 using either a traditional or split-dose @entity2 solution for bowel preparation. The primary outcome was colon cleansing based on the Ottawa Bowel Preparation Score (OBPS). RESULTS: On an intention-to-treat (ITT) basis, a total of 109 and 105 @entity0 were included in the @entity3 and LRB arms, respectively, with 116 and 98 @entity0 , respectively, for the per-protocol (PP) analysis. Although there was no difference in the mean total OBPS between the @entity3 or LRB arms in either the ITT or PP analysis, the threshold for non-inferiority was not met. @entity0 acceptance of the regimens was higher in the LRB arm than in the @entity3 arm in the ITT and PP analyses. CONCLUSIONS: This study failed to show the non-inferiority of an LRB in @entity0 receiving bowel preparation with a @entity2 -based solution. A @entity3 should be prescribed when using a @entity2 bowel preparation. TRIAL REGISTRATION NUMBER: This trial is registered at ClinicalTrials.gov (NCT01454388).

title: Low-residue breakfast during the preparation for colonoscopy using a XXXX electrolyte solution: a randomised non-inferiority trial.

answer: @entity1


abstract: OBJECTIVE: Bakumondo-to (Maimendong tang) is a traditional oriental herbal medicine that has been used as an antitussive agent. We previously demonstrated that Bakumondo-to attenuates airway hyperresponsiveness induced by @entity4 . However, the mechanism(s) responsible for this effect remains unclear. In the present study, we examined the mechanism whereby Bakumondo-to inhibits @entity4 -induced airway hyperresponsiveness. First, we examined the effect of Bakumondo-to on @entity5 production, which are key mediators to airway hyperresponsiveness after @entity4 exposure. Second, we studied its effects on the vagal neuroeffector transmission, because vagal nerve is likely to play an important role in airway hyperresponsiveness after @entity4 . METHODS: We measured the effects of Bakumondo-to on the concentrations of @entity5 in bronchoalveolar lavage fluid before and after @entity4 . We evaluated the effects of Bakumondo-to on the contraction of @entity0 tracheal smooth muscle evoked by electrical field stimulation (EFS) or the exogenous application of @entity1 ( @entity3 ). Isometric tension of tracheal strips was measured in the presence of @entity7 (10(-6) M) and of @entity6 (10(-6) M). RESULTS: @entity4 caused significant increase in @entity2 ( @entity2 ) and @entity8 (TXB2); however, Bakumondo-to did not affect the increase in these @entity5 . Bakumondo-to (0.01 mg/ @entity9 mg/mL) significantly suppressed the contraction evoked by EFS, but did not affect the @entity3 -evoked contraction, indicating that Bakumondo-to suppressed tracheal smooth muscle contraction pre-junctionally. CONCLUSION: These results suggest that the mechanism by which Bakumondo-to inhibits airway hyperresponsiveness depends on inhibiting the release of @entity1 from vagal nerve terminals.

title: Traditional oriental herbal medicine, Bakumondo-to, suppresses vagal neuro-effector transmission in XXXX trachea.

answer: @entity0


abstract: UNASSIGNED: Interactions between @entity6 and @entity1 regulating systems are poorly characterized but clinically important. @entity2 ( @entity2 ) levels are increased shortly after @entity7 treatment by an unknown mechanism, and this effect is blunted by the previous administration of a calcimimetic in animal studies. Here, we explored further the possible underlying mechanisms of this observation in a randomized crossover placebo-controlled study performed in 18 @entity0 males. Volunteers took either @entity9 (60  mg) or placebo and received a 20  mg @entity7 injection 3  h later. Plasma samples were collected at 15-min intervals and analyzed for intact @entity2 , @entity1 , @entity6 , @entity4 , @entity8 , @entity10 , plasma @entity3 activity (PRA), and @entity5 up to 6  h after @entity7 injection. Urinary electrolyte excretion was also monitored. Subjects under placebo presented a sharp increase in @entity2 levels after @entity7 injection. In the presence of @entity9 , @entity2 levels were suppressed and marginal increase of @entity2 was observed. No significant changes in electrolytes and urinary excretion were identified that could explain the @entity7 -induced increase in @entity2 levels. PRA and @entity5 were stimulated by @entity7 injection but were not affected by previous @entity9 ingestion. Expression of @entity11 , but not @entity12 , was found in parathyroid tissue. In conclusion, our results indicate that @entity7 acutely stimulates @entity2 secretion in the absence of any detectable electrolyte changes in healthy adults. A possible direct effect of @entity7 on parathyroid gland needs further studies.

title: @entity7 stimulation of parathormone in @entity0 : role of the @entity1 -sensing receptor and the XXXX -angiotensin system.

answer: @entity3


abstract: BACKGROUND AND PURPOSE: Posterior reversible @entity1 syndrome is a clinicoradiologic syndrome. Literature regarding associated factors and the prognostic significance of contrast enhancement in posterior reversible @entity1 syndrome is sparse. This study set out to evaluate an association between the presence of enhancement in posterior reversible @entity1 syndrome and various clinical factors in a large series of @entity0 with this syndrome. MATERIALS AND METHODS: From an MR imaging report search that yielded 176 @entity0 with clinically confirmed posterior reversible @entity1 syndrome between 1997 and 2014, we identified 135 @entity0 who had received @entity4 -based contrast. The presenting symptoms, etiology, clinical follow-up, and maximum @entity3 within 1 day of MR imaging were recorded. MRIs were reviewed for @entity2 , MR imaging severity, and the presence and pattern of contrast enhancement. Statistical analyses evaluated a correlation between any clinical features and the presence or pattern of enhancement. RESULTS: Of 135 included @entity0 (67.4% females; age range, 7-82 years), 59 (43.7%) had contrast enhancement on T1-weighted MR imaging, the most common pattern being leptomeningeal (n = 24, 17.8%) or leptomeningeal plus cortical (n = 21, 15.6%). Clinical outcomes were available in 96 @entity0 . No significant association was found between the presence or pattern of enhancement and any of the variables, including sex, age, symptom, MR imaging severity, blood pressure, or outcome (all P > .05 after Bonferroni correction). CONCLUSIONS: The presence or pattern of enhancement in posterior reversible @entity1 syndrome is not associated with any of the tested variables. However, an association was found between MR imaging severity and clinical outcome.

title: Utility and Significance of XXXX -Based Contrast Enhancement in Posterior Reversible @entity1 Syndrome.

answer: @entity4


abstract: A simple and rapid isocratic HPLC assay is presented for the analysis and quantification of @entity0 , i.e., @entity4 , @entity3 , @entity5 , @entity2 and @entity6 in the diet of laboratory animals. The @entity0 were extracted from the diet using 90% @entity1 in water. The analysis for the @entity0 was performed by HPLC using a Whatman PartiSphere C18 column with UV detection. The mobile phase was isocratic @entity1 -water (72:28, v/v) for @entity4 , @entity3 , @entity5 and @entity2 and @entity1 -water (65:35, v/v) for @entity6 . The method was simple with good repeatability (R.S.D. = 4.2-16.1%), reproducibility (R.S.D. = 3.7-19%), and accuracy (R.S.D. = 5.5-23.3%). The detection limit of the @entity0 extracted from the diet was 2 micrograms/g for @entity4 , @entity5 and @entity6 , 20 micrograms/g for @entity2 and 100 micrograms/g for @entity3 . Excellent resolution was achieved between the @entity0 and the constituents of the diet. The method demonstrated applicability to monitoring the formulation of @entity0 in the diet of laboratory animals.

title: Quantification of @entity4 , @entity3 , @entity5 , XXXX and @entity6 by isocratic high-performance liquid chromatography.

answer: @entity2


abstract: UNASSIGNED: Introduction @entity3 ( @entity3 ) are increasingly being used to provide postoperative @entity4 following laparotomy for colorectal surgery. Little is known about their efficacy in comparison with epidural infusion @entity4 (EIA). They are potentially better as they avoid the recognised complications associated with EIA. This study compares these two methods of @entity4 . Outcomes include average @entity2 scores, time to mobilisation and length of stay. Methods This was a 33-month single centre observational study including all @entity0 undergoing elective open or laparoscopic-converted-to-open colorectal resection for both benign and @entity1 . @entity0 received either EIA or @entity3 . Data were collected prospectively and analysed retrospectively. Results A total of 95 @entity0 were identified. Indications for surgery, operation and complications were recorded. The mean time to mobilisation was significantly shorter in @entity0 who had @entity3 compared with EIA @entity0 (2.4 vs 3.5 days, p<0.05). There was no difference in postoperative @entity2 scores or length of stay. Conclusions @entity3 provide equivalent @entity4 to EIA and avoid the recognised potential complications of EIA. They are associated with a shorter time to mobilisation. Their use should be adopted more widely.

title: XXXX provide equivalent @entity4 to epidurals following laparotomy for colorectal surgery.

answer: @entity3


abstract: PURPOSE: To assess the potential role of intravascular magnetic resonance (MR) imaging with receiver coils mounted to an inflatable balloon in characterizing @entity2 plaque. MATERIALS AND METHODS: Twelve @entity0 @entity3 with @entity2 changes were studied with a 5-F imaging balloon catheter equipped with a single-loop wire receiver coil. Imaging was performed with an open-configuration 0.5-T (n = 6) or a 1.5-T (n = 6) MR system, with T1- and T2-weighted sequences. Histologic analysis was the reference standard, and MR images were analyzed with regard to vessel wall thickness, @entity1 , and components. RESULTS: Images acquired at 1.5 T were characterized by better in-plane resolution (117 x 104 microm). Resolution at 0.5 T (234 x 178 microm) was sufficient to discriminate the wall layers. On T2-weighted images, adventitia, media, and thickened intima could be discriminated. T1-weighted images did not permit differentiation between wall layers. There was good correlation between MR and histologic measurements of wall thickness (r = .97) and @entity1 (r = .98). Plaque characterization was possible on T2-weighted images. Calcified plaque was identified as areas of low signal intensity (134 +/- 98) and could be differentiated from fibrous structures containing collagen (1,968 +/- 680) or fatty components (762 +/- 394). CONCLUSION: Intravascular MR imaging on the basis of the balloon catheter design enables differentiation of wall layers and plaque components.

title: Intravascular MR imaging of @entity2 plaque: ex vivo analysis of XXXX femoral arteries with histologic correlation.

answer: @entity0


abstract: BACKGROUND: @entity2 has an overall 5-year survival of less than 5%. Similarly, @entity5 has a mortality: incidence ratio of 0.99. The aim of this study was to determine the prevalence of @entity6 and @entity7 ( @entity7 ) overexpression and to identify a possible predictive role in @entity0 with these two @entity1 . MATERIALS AND METHODS: We performed a retrospective study on archival specimens of subjects with hepatocellular and @entity8 . @entity6 and @entity7 overexpression were evaluated by immunohistochemistry. RESULTS: Thirty-three @entity0 with @entity8 and 25 @entity0 with @entity2 were identified. The mean age was 71.7 years for @entity0 with @entity8 and 66 years for @entity0 with @entity2 . Two @entity0 with @entity2 and none with @entity5 overexpressed @entity6 , while 2 @entity0 with @entity8 and 1 @entity0 with @entity2 overexpressed @entity7 . CONCLUSION: @entity6 and @entity7 are not significantly overexpressed in either @entity1 . There appears to be no role for the use of trastuzumab in either @entity1 . Similarly, while there appears to be no role for @entity4 kinase inhibitors in the treatment of @entity2 , further larger studies are necessary in pancreatic @entity3 .

title: XXXX and @entity7 ( @entity7 ) overexpression in hepatocellular and @entity8 .

answer: @entity6


abstract: BACKGROUND/AIMS: Licorice has been used to treat @entity2 , including palpitations, in both Eastern and Western societies for thousands of years. It has been reported that @entity11 (GA), an aglycone @entity10 extracted from licorice root, exerts protective effects on the cardiovascular system, limits @entity7 sizes and protects against the development of @entity4 . However, the mechanisms underlying the effects of @entity11 on the cardiovascular system remain poorly understood. This study aimed to determine the mechanisms underlying the protective effects of GA against lethal @entity4 induced via @entity1 -reperfusion in @entity0 hearts, and to examine its electropharmacological properties. MATERIALS AND METHODS: Anesthetized @entity0 were divided into control (CTL), GA5, GA10, and GA20 groups. GA was administered intravenously 15 min before the occlusion of the left anterior descending coronary artery, at dosages of 5, 10 and 20 mg/kg, respectively. Single ventricular myocytes were isolated using enzymolysis. The whole-cell patch clamp technique was utilized to record Ica, L, Ito and action potentials (APs). RESULTS: During reperfusion, the incidence of @entity9 ( @entity9 ) was decreased in each of the groups compared with the CTL group (p<0.05). The @entity6 ( @entity6 )/ @entity9 score was significantly decreased in the GA20 group. @entity8 ( @entity8 ) were prolonged by GA; both L-type @entity3 current (Ica-L) and transient outward @entity5 current (Ito) were blocked in a concentration-dependent manner by GA. CONCLUSION: These results suggest that GA attenuates both the susceptibility to and the incidence of fatal @entity4 during reperfusion in @entity0 hearts via the prolongation of the APD and the inhibition of both Ica-L and Ito. GA appears to be a promising antiarrhythmic agent in the setting of @entity1 /reperfusion.

title: @entity11 protects the heart from @entity1 /reperfusion injury by attenuating the susceptibility and incidence of fatal XXXX during the reperfusion period in the @entity0 hearts.

answer: @entity4


abstract: BACKGROUND: Hemeproteins such as free myoglobin can undergo autoxidation and catalyse lipid peroxidation, increasing oxidative stress. @entity4 phosphokinase (CPK) elevation is a marker for free myoglobin after myocyte damage. Since oxidative injury is a key mechanism of @entity1 , we hypothesised that serum CPK levels correlate with mortality and need for inotropic medication and duration of inotropic support, i.e. shock, among critically injured @entity0 . METHODS: We conducted a retrospective review of 17,847 @entity0 admitted to a single @entity2 Intensive Care Unit over 9 years. 2583 patients with serum CPK levels were included in the analysis. @entity0 data were collected continuously into an electronic ICU repository. Univariate analysis was accomplished using Spearman correlation and the Mann-Whitney U test. Propensity score adjustment models accounting for potential confounders were used to assess the independent effect of CPK level on mortality, need for inotropic support, and duration of inotropic support. RESULTS: Median CPK was significantly higher in @entity0 who died (916 [IQR 332, 2472] vs. 711 [253, 1971], p=0.004) and in those who required inotropic medications (950 [353, 2525] vs. 469 [188, 1220], p<0.001). After adjusting for propensity score and potential confounders the odds of mortality increased by 1.10 (95% CI 1.02-1.19, p=0.020) and the odds of inotropic medication use increased by 1.30 (95% CI 1.22-1.38, p<0.001) per natural log unit increase in CPK. There was a significant association between CPK level and duration of inotropic support (Spearman's rho .237, p<0.001) that remained significant in a propensity score-adjusted model. CONCLUSION: In critically injured patients, elevated serum CPK level is independently associated with mortality, need for inotropic medication, and duration of inotropic support. This study is the first to evaluate the relationship of CPK level and mortality in addition to surrogate measures of shock in a population of critically injured @entity0 . If these associations are verified prospectively, there may be a role for treatment with @entity6 reductants, such as @entity5 , to mitigate the effects of @entity3 .

title: Elevated serum XXXX phosphokinase is associated with mortality and inotropic requirement in critically injured adults.

answer: @entity4


abstract: UNASSIGNED: OBJECT Case selection for the surgical treatment of @entity4 ( @entity4 ) of the eloquent motor area remains challenging. The aim of this study was to determine the risk factors for worsened @entity2 after surgery in @entity0 with this disorder. METHODS At their hospital the authors retrospectively studied 48 consecutive @entity0 with @entity4 involving motor cortex and/or the descending pathway. All @entity0 had undergone preoperative functional MRI (fMRI) and diffusion tensor imaging (DTI), followed by resection. Both functional and angioarchitectural factors were analyzed with respect to the change in @entity2 . Functional factors included @entity1 ( @entity1 ) on DTI and lesion-to-activation area distance (LAD) and cortical reorganization on fMRI. Based on preoperative @entity2 , the changes in @entity2 at 1 week and 6 months after surgery were defined as short-term and long-term surgical outcomes, respectively. Statistical analysis was performed using the statistical package SPSS (version 20.0.0, IBM Corp.). RESULTS Twenty-one @entity0 (43.8%) had worsened @entity2 1 week after surgery. However, only 10 @entity0 (20.8%) suffered from @entity2 worsening 6 months after surgery. The @entity1 was significantly correlated with short-term (p < 0.001) and long-term (p < 0.001) surgical outcomes. For long-term outcomes, @entity0 in the 5 mm >=  @entity1 > 0 mm (p = 0.009) and @entity1 > 5 mm (p < 0.001) categories were significantly associated with a lower risk of permanent motor worsening in comparison with @entity0 in the @entity1 = 0 mm group. No significant difference was found between @entity0 in the 5 mm >=  @entity1 > 0 mm group and @entity1 > 5 mm group (p = 0.116). Nidus size was the other significant predictor of short-term (p = 0.021) and long-term (p = 0.016) outcomes. For long-term outcomes, the area under the ROC curve (AUC) was 0.728, and the cutoff point was 3.6 cm. Spetzler-Martin grade was not associated with short-term surgical outcomes (0.143), although it was correlated with long-term outcomes (0.038). CONCLUSIONS An @entity5 with a nidus in contact with tracked eloquent fibers ( @entity1 = 0) and having a large size is more likely to be associated with worsened @entity2 after surgery in @entity0 with eloquent motor area @entity4 . Surgical treatment in these @entity0 should be carefully considered. In @entity0 with an @entity1 > 5 mm, radical resection may be considered to eliminate the risk of @entity3 .

title: Risk factors for worsened @entity2 after the surgical treatment of XXXX of the eloquent motor area.

answer: @entity4


abstract: @entity4 frequently recurs in @entity0 even after resection with curative intent. The majority of these are early recurrences and are associated with @entity1 , thus not amenable to repeat resection. Here we report a @entity0 who underwent completion pancreatectomy for a metachronous @entity4 . This @entity0 initially presented with painless @entity5 and computed tomography (CT) revealed a mass in the head of the pancreas. Brushings obtained at endoscopic retrograde cholangiopancreatography (ERCP) were positive for @entity3 . This @entity0 then underwent a Whipple procedure and final pathology demonstrated @entity4 . Adjuvant therapy included @entity2 and @entity6 . This @entity0 was followed with physical examinations and serial laboratory and imaging studies. There was no evidence of disease for four years at which time and sharp elevation in CA-19-9 was found. Subsequent imaging revealed a mass in the remnant pancreas. Curative intent completion pancreatectomy was then performed which confirmed the presence of @entity4 . This was followed by adjuvant @entity2 based chemotherapy and chemoradiation. One year later the @entity0 is alive with no evidence of disease. Thus, in highly selected @entity0 with recurrent or metachronous @entity4 , repeat pancreatectomy can be considered, but the course of treatment should be considered in a multidisciplinary setting.

title: Resection of metachronous XXXX 4  years after pancreaticoduodenectomy for stage III @entity4 .

answer: @entity4


abstract: PURPOSE: To determine if there is a difference in intervention patency for @entity3 ( @entity3 ) and occlusion between @entity0 with autogenous hemodialysis @entity2 and those with grafts. MATERIAL AND METHODS: A retrospective study was performed from March 1998 to September 2005 identifying all @entity0 with autogenous @entity2 and synthetic grafts who underwent percutaneous angioplasty and/or stent placement for @entity3 . This study cohort consisted of 38 @entity0 (22 with @entity2 and 16 with grafts). Age, sex, type of access, location and side of the access, location and side of the @entity3 , presence of @entity1 , previous hemodialysis catheter placement, date and type of interventions, and outcomes were recorded. The patency of each intervention was estimated by using the Kaplan-Meier survival curves. Univariate and multivariate analysis of the variables were performed. RESULTS: Eighty-nine interventions were performed; 83 were angioplasties and six were stent placements. Previous catheter placement on the side of the @entity3 occurred in 29 of the 38 @entity0 (76%). Technical and clinical success of the interventions were 93.3% and 94.4% respectively. The intervention or primary patency rates +/- standard errors at 3, 6, and 9 months in the fistula group were 88.5% +/- 4.8, 59.4% +/- 7.6, and 46% +/- 7.9, respectively. In the graft group, the rates were 78.1% +/- 7.3, 40.7% +/- 9, and 16% +/- 7.3, respectively. With multivariate analysis, intervention patency remained significantly longer for @entity2 (P .014) and in @entity0 who did not have a previous catheter (P .001). CONCLUSION: Longer intervention-free survival for @entity3 was observed in @entity0 with autogenous @entity2 compared with grafts and in @entity0 who did not previously undergo hemodialysis catheter insertion.

title: Patency of endovascular treatment for XXXX : is there a difference between dialysis @entity2 and grafts?

answer: @entity3


abstract: UNASSIGNED: @entity1 is associated with @entity2 by certain types of @entity3 ). The gene variants differ in immune responses and oncogenic potential. The @entity5 proteins encoded by high-risk HPV play a key role in cellular transformation. HPV-33 and HPV-58 types are highly prevalent among Chinese @entity0 . To study the gene intratypic variations, polymorphisms and positive selections of HPV-33 and HPV-58 E6/E7 in southwest China, HPV-33 (E6, E7: n = 216) and HPV-58 (E6, E7: n = 405) @entity5 genes were sequenced and compared to others submitted to GenBank. Phylogenetic trees were constructed by Maximum-likelihood and the Kimura 2-parameters methods by MEGA 6 (Molecular Evolutionary Genetics Analysis version 6.0). The diversity of secondary structure was analyzed by PSIPred software. The selection pressures acting on the E6/E7 genes were estimated by PAML 4.8 (Phylogenetic Analyses by Maximun Likelihood version4.8) software. The positive sites of HPV-33 and HPV-58 E6/E7 were contrasted by ClustalX 2.1. Among 216 HPV-33 E6 sequences, 8 single @entity4 mutations were observed with 6/8 non-synonymous and 2/8 synonymous mutations. The 216 HPV-33 E7 sequences showed 3 single @entity4 mutations that were non-synonymous. The 405 HPV-58 E6 sequences revealed 8 single @entity4 mutations with 4/8 non-synonymous and 4/8 synonymous mutations. Among 405 HPV-58 E7 sequences, 13 single @entity4 mutations were observed with 10/13 non-synonymous mutations and 3/13 synonymous mutations. The selective pressure analysis showed that all HPV-33 and 4/6 HPV-58 E6/E7 major non-synonymous mutations were sites of positive selection. All variations were observed in sites belonging to major histocompatibility complex and/or B-cell predicted epitopes. @entity6 and R145 (I/N) were observed in both HPV-33 and HPV-58 E6.

title: @entity5 Gene Polymorphisms in XXXX Types-58 and 33 Identified in Southwest China.

answer: @entity3


abstract: UNASSIGNED: This study was designed to investigate the prognostic impact of elevated platelet to lymphocyte ratio (PLR) on survival for @entity2 ( @entity2 ) treated with neoadjuvant chemotherapy in a curative intent. From 2004 to 2014, 153 consecutive @entity0 with @entity2 were included. PLR was measured at first diagnosis. Receiver Operating Characteristic curve analysis was performed to determinate PLR threshold. Cox multivariate model was used to assess correlation between PLR and survival. Cut-off value for PLR was 192, which identified 2 groups of @entity0 : low (n  =  122) and high PLR value (n  =  31). Both groups were comparable by @entity0 (age, sex, ASA score) and @entity1 characteristics (differentiation, @entity4 stage, location). Five year @entity3 ( @entity3 ) was 65%. @entity3 and DFS were reduced in the high PLR group: p  =  0.019 and p  =  0.016, respectively. PLR was associated with increased recurrence (54.8% vs. 35.2%, p  =  0.046) and @entity1 (41.9% vs. 23.8%, p  =  0.043) rates. On multivariate analysis, elevated PLR was associated with decreased DFS (HR  =  2.85, 95%CI  =  1.54-5.26, p  =  0.001) and @entity3 (HR  =  2.47, 95%CI  =  1.21-5.01, p  =  0.012). This study demonstrates that elevated PLR is associated with poor @entity3 and DFS for @entity2 treated with a curative intent and has the potential to be a useful prognostic biomarker for treatment planning.

title: Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 XXXX .

answer: @entity0


abstract: OBJECTIVES: To estimate the prevalence of @entity3 in aged care facilities, and the relationship between cognitive or @entity8 and significant disease. SETTING: 2 large aged care facilities in Auckland, New Zealand, each providing low and high level care. @entity1 : All 161 residents of the facilities were invited to participate. The only exclusion criterion was inability to obtain consent from the individual or designated guardian. 88 @entity1 were recruited-66 females (75%), 22 males (25%) with average age 87.1   years (SD 5.5   years). PRIMARY AND SECONDARY OUTCOME MEASURES: Primary-presence of significant @entity5 (defined as that which in the opinion of the investigators needed treatment or was identified as a @entity1 concern) diagnosed clinically on full dermatological examination by a dermatologist or dermatology trainee. Secondary-functional and cognitive status (Rehabilitation Complexity Scale and Abbreviated Mental Test Score). RESULTS: 81.8% were found to have at least one significant condition. The most common disorders were @entity12 42 (47.7%), @entity10 13 (14.8%), @entity7 11 (12.5%) and @entity9 in situ 9 (10.2%). Other findings were @entity9 7 (8%), bullous pemphigoid 2 (2.3%), @entity6 2 (2.3%), @entity11 (2.3%) and @entity0 (1.1%). @entity2 was more common in those with @entity8 compared with those with serious @entity8 (OR 3.69; 95% CI 1.1 to 12.6, p=0.04). No significant association was found between @entity5 and @entity4 . CONCLUSIONS: A high rate of @entity3 was found. Findings ranged from frequent but not life-threatening conditions (eg, @entity12 ), to those associated with a significant morbidity (eg, @entity7 , @entity11 and bullous pemphigoid), to potentially life-threatening (eg, @entity9 , @entity6 and @entity0 ). Those with less significant @entity4 were found to be at greater risk of inflammatory dermatoses.

title: XXXX in the older age group: a cross-sectional study in aged care facilities.

answer: @entity3


abstract: OBJECTIVE: We aimed to assess whether the dosing regimen of @entity3 shows a relationship to mortality in critically ill @entity0 with @entity2 ( @entity2 ). BACKGROUND: @entity3 may decrease mortality in @entity0 with @entity2 ; however, the optimal dosing regimen remains uncertain. METHODS: We conducted a post-hoc analysis of a multicenter, randomized trial of weekly @entity3 versus placebo in @entity0 with moderate and severe @entity2 admitted to intensive care. We assessed whether the cumulative dosage of @entity3 was differentially associated with all-cause @entity0 mortality evaluated at 6 months after injury. RESULTS: There was a nonlinear relationship between dose and mortality (P = 0.008) that remained after adjustment for site and severity of illness (P = 0.01). Six-month mortality was lower in randomized @entity0 who received 1 [adjusted hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.33-1.01; P = 0.06] or 2 doses of @entity3 (HR 0.31, 95% CI 0.12-0.80; P = 0.02) compared with those who received no doses. No benefit was seen with 3 doses (HR 1.55, 95% CI 0.66-3.62; P = 0.33). There was no differential effect of dose on functional neurological outcomes. Results across subgroups and secondary intention to treat analyses were consistent with primary findings. CONCLUSIONS: This post-hoc, hypothesis-generating analysis found potential reductions in mortality following 1 or 2 weekly doses of 40,000 IU of @entity3 in intensive care unit @entity0 with moderate or severe @entity2 , but not with 3 doses. These findings will inform the design of future trials of @entity3 in critically ill @entity0 with @entity2 and @entity1 .

title: @entity3 to Reduce Mortality in XXXX : A Post-hoc Dose-effect Analysis.

answer: @entity2


abstract: UNASSIGNED: @entity0 suffering from @entity2 often experience @entity7 even after the remission of mood symptoms, and many antidepressant drugs do not affect, or impair, memory in animals and @entity0 . However, some antidepressant drugs, after a single dose, enhance cognition in @entity0 (Harmer et al., 2009). To compare different classes of antidepressant drugs for their potential as memory enhancers, we used a version of the novel object recognition task in which @entity1 spontaneously forget objects 24 hr after their presentation. Antidepressant drugs were injected systemically 30 min before or directly after the training phase (Session 1 [S1]). Post-S1 injections were used to test for specific memory-consolidation effects. The @entity6 reuptake inhibitors @entity13 and @entity9 , as well as the @entity3 @entity6 reuptake inhibitor @entity8 , injected prior to S1 significantly enhanced recognition memory. In contrast, the @entity3 reuptake inhibitors @entity4 and @entity5 and the cyclic antidepressant drugs @entity11 and @entity10 did not enhance recognition memory. Post-S1 injection of either @entity13 or @entity4 significantly enhanced recognition memory, indicating an effect on memory consolidation. The fact that @entity4 had an effect only when injected after S1 suggests that it may counteract its own consolidation-enhancing effect by interfering with memory acquisition. However, pretreatment with @entity4 did not attenuate @entity13 's memory-enhancing effect. The D1/5-receptor antagonist @entity12 blunted @entity13 's memory-enhancing effect, indicating a role of dopaminergic transmission in @entity13 -induced recognition memory enhancement. Our results suggest that antidepressant drugs specifically inhibiting @entity6 reuptake enhance cognition and may be beneficial in the treatment of @entity2 . (PsycINFO Database Record

title: Antidepressant Drugs Specifically Inhibiting XXXX Reuptake Enhance Recognition Memory in @entity1 .

answer: @entity6


abstract: PURPOSE: To demonstrate the protective effect of @entity6 ( @entity6 ) signaling on the cardiovascular system, we conducted this study to show that the @entity8 analog (lixisenatide) could inhibit @entity4 ( @entity4 ) development in @entity2 . METHODS: Lixisenatide was injected subcutaneously 7  days after @entity3 preparation. We evaluated reactive @entity1 species (ROS) expression by @entity7 staining and @entity9 ( @entity9 ; the oxidation product of DNA) by immunohistochemical staining. We also analyzed the effect of @entity6 signaling on the inflammatory response. Histopathological examination was done on day 28, and the @entity4 dilatation ratio was calculated. RESULTS: On day 14, ROS expression and @entity9 -positive cells in the @entity3 walls were seen to have been significantly decreased by lixisenatide treatment. Western blot analysis showed decreased @entity5 expression. There was significantly reduced @entity0 necrosis factor-a mRNA expression in the @entity3 walls and @entity10 -positive cell infiltration in the @entity3 walls. On day 28, it was evident that the lixisenatide had dramatically reduced @entity3 development in the @entity2 . CONCLUSION: @entity6 elevation inhibits @entity4 development in @entity2 through its anti-oxidant and anti-inflammatory effects. Thus, @entity6 could be a potent pharmacological target for @entity4 treatment.

title: XXXX prevented @entity4 development in @entity2 .

answer: @entity6


abstract: AIM: To evaluate the role of ultrasonography for differentiating @entity5 due to @entity2 , @entity1 and @entity3 . METHODS: Ultrasonography of the neck nodes was carried out prior to FNAC in 192 @entity0 using a 10 mHz linear transducer. The sonographic findings were then correlated with the definitive tissue diagnosis obtained by FNAC or lymph node biopsy. RESULTS: The most significant distinguishing feature was strong internal echoes seen in 84% of tubercular lymph nodes. This finding was found in only 11% of metastatic nodes and absent in @entity4 . The other findings such as L/S ratio, irregular margins, hypoechoic center, fusion tendency, peripheral halo and absent hilus were helpful in differentiating reactive from diseased nodes but showed considerable overlap in the 3 groups of tubercular, metastatic and @entity3 lymph nodes. CONCLUSION: Ultrasonography is noninvasive and can give useful clues in the diagnosis of @entity5 . It should be interpreted in conjunction with FNAC result. Ideally ultra-sonographic guided FNAC should be obtained from the sonographically most representative node. In FNAC indeterminate cases, sonographic features may obviate the need for an invasive lymph node biopsy.

title: Usefulness of ultrasonography for the evaluation of XXXX .

answer: @entity5


abstract: BACKGROUND: @entity11 phosphorylase (PyNPase) is identical to the protein, @entity6 ( @entity6 ), which has angiogenic activity. The physiological roles of PyNPase activity in the uterus and ovary are not known. In this study, we measured PyNPase activity in normal tissues of the uterus, ovary, and lymph nodes, and in benign and malignant lesions of these organs, and we considered the clinical implications of PyNPase activity in the uterus and ovary. METHODS: Tissue samples were obtained from 163 @entity0 (whose diseases are listed below) during surgery. PyNPase activity was measured spectrophotometrically, by monitoring the formation of @entity9 . RESULTS: Mean PyNPase activity in tissues from the lesions of @entity0 with @entity2 (n = 20), uterine @entity7 (n = 26), @entity8 (n = 23), @entity3 (n = 46), @entity3 (n = 21), and @entity3 (n = 27) was significantly greater than that in the corresponding normal tissues. The PyNPase activity in the normal endometrium was significantly higher in the secretory phase than in the proliferative phase. The activity in normal or metastatic lymph nodes was significantly greater than that in normal tissues of the uterus and ovary. Mean PyNPase activity in cancerous cervical tissues was significantly greater than that in cancerous endometrial tissues or cancerous ovarian tissues. There were no significant differences in PyNPase activity in @entity2 , @entity3 tissues according to @entity2 stage. The enzyme activity appeared to be greater in histopathological G3 grade @entity7 than in G1 and G2 @entity7 . The enzyme activity in mucinous @entity4 was significantly lower than that in serous, endometrioid, and @entity10 . All @entity0 with cervical @entity5 with PyNPase activity greater than 500 nmol/min per mg protein exhibited lymph node @entity1 . CONCLUSION: Increased PyNPase activity consistently reflected @entity2 , and varying levels of activity were seen in different histologic cell types. This enzyme activity may be involved in cervical @entity5 , in normal and metastatic lymph nodes, and in the normal, secretory phase in the endometrium.

title: XXXX phosphorylase activity in normal tissues of the uterus and ovary and in benign and malignant lesions of these organs.

answer: @entity11


abstract: OBJECTIVES: Microbial @entity8 ( @entity8 ), such as @entity4 -binding oligomerization domains (NODs), are essential for @entity0 innate immune response. This study was designed to determine the effect of @entity10 and @entity6 agonist on innate immune responses and antitumor activity in @entity3 ( @entity3 ) cells. MATERIALS AND METHODS: NODs expression was examined by RT-PCR, and @entity2 production by NODs agonist was examined by ELISA. Western blot analysis was performed to determine the MAPK activation in response to their agonist. Cell proliferation was determined by @entity1 assay. Flow cytometry and Western blot analysis were performed to determine the @entity7 -induced cell death. RESULTS: The levels of NODs were apparently expressed in @entity3 cells. NODs agonist, Tri-DAP and @entity7 , led to the production of @entity2 and MAPK activation. @entity6 agonist, @entity7 , inhibited the proliferation of YD-10B cells in a dose-dependent manner. Also, the ratio of @entity5 -positive cells and cleaved @entity9 was increased by @entity7 treatment in YD-10B cells, suggesting that @entity7 -induced cell death in YD-10B cells may be owing to apoptosis. CONCLUSIONS: Our results indicate that NODs are functionally expressed in @entity3 cells and can trigger innate immune responses. In addition, @entity6 agonist inhibited cell proliferation and induced apoptosis. These findings provide the potential value of @entity7 as novel candidates for antitumor agents of @entity3 .

title: @entity6 ( XXXX ) activation induces apoptosis of @entity0 @entity3 cells.

answer: @entity6


abstract: BACKGROUND: @entity3 ( @entity3 ) has become one of the most common causes of @entity1 in developed countries. @entity2 result in a loss of independence and @entity0 ' quality of life. Cognitive rehabilitation aims to promote @entity0 ' skills to achieve their highest degree of personal autonomy. New technologies such as virtual reality or interactive video allow developing rehabilitation therapies based on reproducible Activities of Daily Living (ADLs), increasing the ecological validity of the therapy. However, the lack of frameworks to formalize and represent the definition of this kind of therapies can be a barrier for widespread use of interactive virtual environments in clinical routine. OBJECTIVES: To provide neuropsychologists with a methodology and an instrument to design and evaluate cognitive rehabilitation therapeutic interventions strategies based on ADLs performed in interactive virtual environments. METHODS: The proposed methodology is used to model therapeutic interventions during virtual ADLs considering @entity2 , expected abnormal interactions and therapeutic hypotheses. It allows identifying abnormal behavioural patterns and designing interventions strategies in order to achieve errorless-based rehabilitation. RESULTS: An ADL case study ('buying bread') is defined according to the guidelines established by the ADL intervention model. This case study is developed, as a proof of principle, using interactive video technology and is used to assess the feasibility of the proposed methodology in the definition of therapeutic intervention procedures. CONCLUSIONS: The proposed methodology provides neuropsychologists with an instrument to design and evaluate ADL-based therapeutic intervention strategies, attending to solve actual limitation of virtual scenarios, to be use for ecological rehabilitation of @entity2 in daily clinical practice. The developed case study proves the potential of the methodology to design therapeutic interventions strategies; however our current work is devoted to designing more experiments in order to present more evidence about its values.

title: Modelling Ecological Cognitive Rehabilitation Therapies for Building Virtual Environments in XXXX .

answer: @entity3


abstract: UNASSIGNED: Anti- @entity1 drugs are discussed as high risk substances in regard to @entity0 health and considered as problematic for the environment. They are of potential environmental relevance due to their poor biodegradability and toxicological properties. @entity3 ( @entity7 ) is an antimetabolite that was introduced in the pharmaceutical market in the 40's and still today is one of the most consumed cytotoxic compounds around the world. In the present study @entity7 was only partially biodegraded in the closed bottle test (CBT). Therefore, it was submitted to three different advanced oxidation processes (AOPs): UV/ @entity6 , UV/ @entity8 / @entity6 and UV/ @entity4 . The irradiation was carried out with a @entity5 medium-pressure lamp during 256min whereas the analytical monitoring was done through LC-UV-MS/MS and DOC analysis. @entity7 was easily removed in all the irradiation experiments, while the highest mineralization values and rates were achieved by the UV/ @entity8 / @entity6 treatment. The lowest resulted from the UV/ @entity6 reactions. The UV/ @entity6 treatment resulted in little biodegradable transformation products (TPs). However, the same treatment resulted in a reduction of the @entity2 of @entity7 by forming less toxic TPs. Analysis by LC-UV-MS/MS revealed the existence of nine TPs formed during the photo-catalytic treatments. The pH of the solutions decreased from 6.4 (t 0min) to 5.15 in the UV/ @entity6 and from 6.4 (t 0min) to 5.9 in the UV/ @entity4 at the end of the experiments. The initial pH of the UV/ @entity8 / @entity6 experiments was adjusted to 5 and after the addition of @entity6 the pH decreased to around 3 and remained in this range until the end of the treatments.

title: Removal of the anti- @entity1 drug @entity3 from water by advanced oxidation processes: Aerobic biodegradation and XXXX studies after treatment.

answer: @entity2


abstract: The alpha chain of the interleukin 2 receptor ( @entity5 ; Tac) was targeted in clinical trials with @entity3 using murine anti-Tac antibody. Of 19 @entity0 , a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hypothesis that the maintenance of the long-term response after treatment might be related to induction of a network of anti-idiotypic antibodies, as proposed in other @entity1 settings. In contrast to anti-Tac non-responders, the @entity0 was found to have produced a @entity4 ( @entity4 ) response, and specifically an anti-idiotypic (Ab2) response, that was readily detectable by standard assays 4 years after treatment. Using phage display antibody libraries, this response was shown to be monoclonal, consisting of a single IgG1,kappa antibody of moderate affinity. No evidence was found for anti-anti-idiotypic (Ab3) antibodies with reactivity for sTac, which might alternatively have maintained an autogenic human anti-Tac antibody response. An area of limited homology was noted between the Ab2 antibody and the @entity5 in the domain of @entity2 binding, but no binding of Ab2 to @entity2 could be shown that might have reduced endogenous ligand ( @entity2 ) concentrations. Similarly, no anti-anti-idiotypic (T3) T cell response was detected. Thus, we are unable to confirm features of idiotypy that could suggest a role in maintaining an anti- @entity1 response by anti-Tac antibody therapy.

title: Examination of a role for idiotypy in the disease remission of a long-term survivor of XXXX treated with anti-Tac antibody.

answer: @entity3


abstract: AIMS: Increased @entity4 ( @entity4 ) is a common finding in cardiology. It is not known how often hereditary transthyretin-related @entity2 ( @entity9 - @entity7 ) is responsible for @entity4 . Several therapeutic modalities for @entity9 - @entity7 are currently in clinical trials; thus, it is important to establish the prevalence of @entity8 mutations ( @entity9 ) and the clinical characteristics of the @entity0 with @entity9 - @entity7 . METHODS AND RESULTS: In a prospective multicentre, cross-sectional study, the @entity8 gene was sequenced in 298 consecutive @entity0 diagnosed with increased @entity4 in primary cardiology clinics in France. Among the included @entity0 , median (25-75th percentiles) age was 62 [50;74]; 74% were @entity0 ; 23% were of African origin; and 36% were in NYHA Class III-IV. Median @entity4 was 18 (16-21) mm. Seventeen (5.7%; 95% confidence interval [CI]: [3.4;9.0]) @entity0 had @entity9 of whom 15 (5.0%; 95% CI [2.9;8.2]) had @entity9 - @entity7 . The most frequent mutations were @entity11 (n = 8), @entity10 (n = 2), and @entity12 (n = 2). All @entity9 - @entity7 @entity0 were older than 63 years with a median age of 74 [69;79]. Of the 15 @entity0 with @entity9 - @entity7 , 8 were of African descent while 7 were of European descent. In the African descendants, @entity9 - @entity7 median age was 74 [72;79] vs. 55 [46;65] years in non- @entity9 - @entity7 (P < 0.001). In an adjusted multivariate model, African origin, @entity1 , @entity3 , electrocardiogram (ECG) low voltage, and late @entity6 enhancement (LGE) at cardiac-magnetic resonance imaging were all independently associated with @entity9 - @entity7 . CONCLUSION: Five per cent of @entity0 diagnosed with @entity5 have @entity9 - @entity7 . Mutated transthyretin genetic screening is warranted in elderly subjects with increased @entity4 , particularly, those of African descent with @entity1 , @entity3 , ECG low voltage, or LGE.

title: Prevalence and clinical phenotype of @entity2 in XXXX with increased @entity4 .

answer: @entity0


abstract: BACKGROUND: There are few reports in the literature of the risks associated with second @entity3 in @entity0 with @entity2 ( @entity2 ). We hypothesise that @entity2 increases the risk of complications. AIMS: We sought to determine if @entity2 is associated with a higher risk of @entity1 and blood transfusion at the time of dilation and evacuation (D_E). MATERIALS AND METHODS: The records of 612 consecutive @entity0 undergoing abortion at 15-24  weeks of gestation were reviewed. @entity0 characteristics, need for blood transfusion, estimated @entity1 (EBL) during the abortion and other complications were compared between @entity0 with and without ultrasound-documented @entity2 . RESULTS: Eighty-seven of 612 (14.2%, 95% CI 11.5-17.2%) @entity0 had ultrasound-documented @entity2 . The rate of blood transfusion was 3.4 and 1.3% in the group with @entity2 and without @entity2 , respectively (adjusted relative risk (RR  =  2.8, 95% CI 0.7-11.3). An estimated @entity1 of 500  cc or greater during the D_E procedure was observed in 12.6% of @entity0 in the @entity2 group compared with 4.2% of @entity0 in the group without @entity2 (adjusted RR 3.1, 95% CI 1.4-6.8, P  =  0.004). CONCLUSIONS: Second- @entity3 in @entity0 with @entity2 is associated with a higher risk of @entity1 of 500  cc or greater. Our study represents a larger sample size of @entity0 with @entity2 undergoing second- @entity3 than previously reported in the literature. @entity0 with @entity2 may have a higher estimated @entity1 and may require access to blood transfusion.

title: Placenta praevia and the risk of adverse outcomes during second XXXX : A retrospective cohort study.

answer: @entity3


abstract: We report two cases of @entity2 treatment in couples where males suffered from @entity3 ( @entity3 ) and a total absence of motile sperm in the ejaculate. A total of three ICSI cycles was carried out. In all cycles, viable ejaculated or testicular spermatozoa were selected using the @entity1 ( @entity1 ) test. Case 1: In the first ICSI cycle total fertilization failure occurred after using ejaculated spermatozoa. In the following cycle testicular spermatozoa were used for ICSI, resulting in 75% fertilized oocytes and a pregnancy. Case 2: In the same ICSI cycle 50% of the oocytes were injected with ejaculated and 50% with testicular spermatozoa. The fertilization rates were 44 and 56% respectively and high quality embryos were achieved in both groups. One single embryo derived from testicular sperm was transferred with a resulting singleton pregnancy. In conclusion, testicular sperm for ICSI seem to have reliable fertilization capacity in @entity0 with @entity3 , while ejaculated sperm, even if tested viable, seem more unpredictable. @entity1 test for selection of viable sperm for ICSI is recommended when ejaculated as well as testicular sperm are used for ICSI.

title: Different fertilization rates between immotile testicular spermatozoa and immotile ejaculated spermatozoa for ICSI in XXXX with @entity3 : case reports.

answer: @entity0


abstract: OBJECTIVES: Inflammation is a well-established risk factor for the development of @entity3 ( @entity3 ) and @entity6 ( @entity6 ). However, less is known about its influence on the outcome of @entity6 . The aim of this study was to determine if blood biomarkers of @entity1 were associated specifically with acute @entity4 ( @entity4 ) or @entity7 ( @entity7 ) in @entity0 with @entity6 . DESIGN: Cross-sectional study. SETTING: @entity0 admitted to the coronary care unit, via the emergency room, at a central county hospital over a 4-year period (1992-1996). @entity0 : In a substudy of @entity2 ( @entity2 ) of 5292 @entity0 admitted to the coronary care unit, we identified 908 @entity0 aged 30-74 years, who at discharge had received the diagnosis of either @entity4 (527) or @entity7 (381). MAIN OUTCOME MEASURES: @entity4 or @entity7 , based on the diagnosis set at discharge from hospital. RESULTS: When adjusted for smoking, age, sex and duration of @entity5 , concentrations of plasma biomarkers of @entity1 (high-sensitivity C reactive protein>2 mg/L (OR=1.40 (1.00 to 1.96) and fibrinogen (p for trend=0.035)) analysed at admission were found to be associated with @entity4 over @entity7 , in an event of @entity6 . A strong significant association with @entity4 over @entity7 was found for blood cell markers of @entity1 , that is, counts of neutrophils (p for trend<0.001), monocytes (p for trend<0.001) and thrombocytes (p for trend=0.021), while lymphocyte count showed no association. Interestingly, eosinophil count (p for trend=0.003) was found to be significantly lower in @entity0 with @entity4 compared to those with @entity7 . CONCLUSIONS: Our results show that, in @entity0 with @entity6 , the blood cell profile and degree of @entity1 at admission was associated with the outcome. Furthermore, our data suggest that a pre-existing low-grade @entity1 may dispose towards @entity4 over @entity7 .

title: Influence of pre-existing @entity1 on the outcome of XXXX : a cross-sectional study.

answer: @entity6


abstract: A 75-year-old @entity0 presented with a 4-month history of a swollen and @entity1 penis. Computed tomography showed a round-shaped mass measuring 3   *   2   cm in the corpus cavernosum. Percutaneous drainage of the penile mass was carried out and a course of antibiotics was prescribed. Viral, fungal and selective bacterial cultures were negative. Total penectomy and urethroperineal @entity2 formation were carried out because of @entity3 . Histopathological diagnosis was xanthogranulomatous @entity5 of the corpus cavernosum. Before surgery, sonourethrography was carried out under general anesthesia. Sonourethrography is an infrequently used modality to observe the male urethra under urinary micturition or injection of saline. We previously reported modified sonourethrography with retrograde jelly injection. In the present case, sonourethrography successfully showed the damaged and deformed urethra including the @entity4 and @entity2 . Although xanthogranulomatous @entity5 is rare, the findings reported here showed the usefulness of sonourethrography for morphological evaluation of the male urethra.

title: Usefulness of sonourethrography for XXXX as a result of xanthogranulomatous @entity5 in the corpus cavernosum of an adult: A case report.

answer: @entity3


abstract: BACKGROUND: Long-distance axonal growth relies on the precise interplay of guidance cues and cell adhesion molecules. While guidance cues provide positional and directional information for the advancing growth cone, cell adhesion molecules are essential in enabling axonal advancement. Such a @entity0 on adhesion as well as guidance molecules can be well observed in dorsal commissural interneurons, which follow a highly stereotypical growth and guidance pattern. The mechanisms and molecules involved in the attraction and outgrowth towards the ventral midline, the axon crossing towards the contralateral side, the rostral turning after midline crossing as well as the guidance along the @entity1 have been intensely studied. However, little is known about molecules that provide the basis for commissural axon growth along the anterior-posterior @entity1 . RESULTS: @entity2 , a recently discovered cell adhesion molecule of the IgCAM superfamily, is highly expressed in dorsolaterally located ( @entity3 ) spinal interneurons. Functional studies inactivating @entity2 by RNA interference (RNAi) or function-blocking antibodies demonstrate that either treatment results in a lack of commissural axon growth along the @entity1 . Moreover, results from RNAi experiments targeting the contralateral side together with binding studies suggest that homophilic @entity2 interactions between ipsilaterally projecting axons and post-crossing commissural axons may be the basis of axonal growth along the @entity1 . CONCLUSIONS: Directed axonal growth of dorsal commissural interneurons requires an elaborate mixture of instructive (guidance) and permissive (outgrowth supporting) molecules. While Wnt and Sonic hedgehog (Shh) signalling pathways have been shown to specify the growth direction of post-crossing commissural axons, our study now provides evidence that homophilic @entity2 interactions are essential for axonal extension along the @entity1 . Interestingly, so far each part of the complex axonal trajectory of commissural axons uses its own set of guidance and growth-promoting molecules, possibly explaining why such a high number of molecules influencing the growth pattern of commissural interneurons has been identified.

title: Rostral growth of commissural axons requires the cell adhesion molecule XXXX .

answer: @entity2